PMID- 28629534
OWN - NLM
STAT- MEDLINE
DCOM- 20180426
LR  - 20180426
IS  - 1875-5364 (Electronic)
IS  - 1875-5364 (Linking)
VI  - 15
IP  - 6
DP  - 2017 Jun
TI  - Heparin-derived oligosaccharide inhibits vascular intimal hyperplasia in 
      balloon-injured carotid artery.
PG  - 442-450
LID - S1875-5364(17)30066-3 [pii]
LID - 10.1016/S1875-5364(17)30066-3 [doi]
AB  - The aims of the present study were to determine the effects of heparin-derived 
      oligosaccharides (HDOs) on vascular intimal hyperplasia (IH) in balloon-injured 
      carotid artery and to elucidate the underlying mechanisms of action. An animal 
      model was established by rubbing the endothelia within the common carotid artery 
      (CCA) in male rabbits. The rabbits were fed a high-cholesterol diet. Arterial IH 
      was determined by histopathological changes to the CCA. Serum lipids were 
      detected using an automated biochemical analysis. Expressions of mRNAs for 
      vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), 
      vascular cell adhesion molecule-1 (VCAM-1), monocyte chemoattractant protein-1 
      (MCP-1), scavenger receptor class B type I (SR-BI), and ATP-binding cassette 
      transporter A1 (ABCA-1) were analyzed using reverse transcription polymerase 
      chain reaction assays. Expressions of VEGF, VCAM-1, MCP-1, SR-BI and ABCA-1 
      proteins were analyzed by Western blotting. Enzyme-linked immunosorbent assays 
      were used to quantify expression levels of VEGF and bFGF. Our results showed that 
      administration of HDO significantly inhibited CCA histopathology and restenosis 
      induced by balloon injury. The treatment with HDOs significantly decreased the 
      mRNA and protein expression levels of VEGF, bFGF, VCAM-1, MCP-1, and SR-BI in the 
      arterial wall; however, ABCA-1 expression level was elevated. HDO treatment led 
      to a reduction in serum lipids (total cholesterol, triglycerides, high-density 
      and low-density lipoproteins). Our results from the rabbit model indicated that 
      HDOs could ameliorate IH and underlying mechanism might involve VEGF, bFGF, 
      VCAM-1, MCP-1, SR-BI, and ABCA-1.
CI  - Copyright (c) 2017 China Pharmaceutical University. Published by Elsevier B.V. All 
      rights reserved.
FAU - Liu, Jie-Ru
AU  - Liu JR
AD  - School of Life Science and Technology, China Pharmaceutical University, Nanjing 
      210009, China.
FAU - Wu, Jie
AU  - Wu J
AD  - School of Life Science and Technology, China Pharmaceutical University, Nanjing 
      210009, China.
FAU - Yu, Xin-Chao
AU  - Yu XC
AD  - School of Life Science and Technology, China Pharmaceutical University, Nanjing 
      210009, China.
FAU - Qian, Xuan
AU  - Qian X
AD  - School of Life Science and Technology, China Pharmaceutical University, Nanjing 
      210009, China.
FAU - Xiong, Rui
AU  - Xiong R
AD  - School of Life Science and Technology, China Pharmaceutical University, Nanjing 
      210009, China.
FAU - Wang, Hui-Fang
AU  - Wang HF
AD  - School of Life Science and Technology, China Pharmaceutical University, Nanjing 
      210009, China.
FAU - Yu, Dan-Feng
AU  - Yu DF
AD  - School of Life Science and Technology, China Pharmaceutical University, Nanjing 
      210009, China.
FAU - Liu, Fei-Fei
AU  - Liu FF
AD  - School of Life Science and Technology, China Pharmaceutical University, Nanjing 
      210009, China.
FAU - He, Shu-Ying
AU  - He SY
AD  - School of Life Science and Technology, China Pharmaceutical University, Nanjing 
      210009, China. Electronic address: heshuying92@126.com.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Chin J Nat Med
JT  - Chinese journal of natural medicines
JID - 101504416
RN  - 0 (ATP Binding Cassette Transporter 1)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Oligosaccharides)
RN  - 0 (Vascular Cell Adhesion Molecule-1)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - ATP Binding Cassette Transporter 1/analysis
MH  - Animals
MH  - Carotid Artery Injuries/*drug therapy/pathology
MH  - Chemokine CCL2/analysis
MH  - Heparin/*therapeutic use
MH  - Hyperplasia
MH  - Male
MH  - Oligosaccharides/*therapeutic use
MH  - Rabbits
MH  - Tunica Intima/*pathology
MH  - Vascular Cell Adhesion Molecule-1/analysis
MH  - Vascular Endothelial Growth Factor A/analysis
OTO - NOTNLM
OT  - Atherosclerosis
OT  - Balloon injury
OT  - Heparin-derived oligosaccharide
OT  - Intimal hyperplasia
EDAT- 2017/06/21 06:00
MHDA- 2018/04/27 06:00
CRDT- 2017/06/21 06:00
PHST- 2016/08/31 00:00 [received]
PHST- 2017/06/21 06:00 [entrez]
PHST- 2017/06/21 06:00 [pubmed]
PHST- 2018/04/27 06:00 [medline]
AID - S1875-5364(17)30066-3 [pii]
AID - 10.1016/S1875-5364(17)30066-3 [doi]
PST - ppublish
SO  - Chin J Nat Med. 2017 Jun;15(6):442-450. doi: 10.1016/S1875-5364(17)30066-3.